| Methods |
No placebo run‐in; inclusion criteria= patients with established Type 2 DM and BP > 75th centile for age and sex, taking no anti‐hypertensive medication; 3‐week double‐blind treatment |
| Participants |
Trandolapril 4 mg: n=12(10 males,2 females); mean age=58(11) years; baseline SBP=168(13) mm Hg, DBP=98(10) mm Hg;
Placebo: n=12(9 males,3 females); mean age=60(12) years; baseline SBP=165(14) mm Hg, DBP=93(6) mm Hg |
| Interventions |
Trandolapril 4 mg once daily;
Placebo;
administered at 8 AM |
| Outcomes |
Trough supine SBP/DBP using mercury sphygmomanometer |
| Notes |
BP change and SD of change not reported; endpoint BP and SD reported; imputed endpoint SD for SD of change; SBP/DBP data from Figure 1, p. 137; Jadad score=2; funding source= Hoechst Marion Rousell |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
